Access cutting-edge ischemic stroke treatment through this clinical trial at a research site in Hartford. Study-provided care at no cost to qualified participants.
Access ischemic stroke specialists in Hartford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ischemic stroke treatment provided free
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Sponsor: Translational Sciences, Inc.
Check if you qualify for this ischemic stroke clinical trial in Hartford, CT
If you're searching for ischemic stroke treatment options in Hartford, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Hartford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ischemic stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.